AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
AAVantgarde Bio presented positive clinical data for its gene therapy AAVB-081 at the EURETINA 2026 congress. The study showed no serious adverse events and early signs of visual improvement in patients with Usher syndrome type 1B.
Why it matters
Advancements in dual-AAV gene therapy offer potential breakthroughs for treating inherited retinal diseases that were previously considered untreatable.
The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease
MILAN, Oct. 04, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its proprietary dual-AAV technology, has today announced the presentation of updated clinical data from the LUCE-1 study and preclinical and clinical development data for AAVB-039 for Stargardt disease at the 26 th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2026) , taking place in Vienna 1-4 October 2026.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in